[1]马为梅,李春花,雷晓琴,等.雷珠单抗玻璃体腔按需注射治疗视网膜分支静脉阻塞继发黄斑水肿疗效研究*[J].陕西医学杂志,2019,(11):1552-1555.
　MA Weimei,LI Chunhua,LEI Xiaoqin,et al.Efficacy of intravitreal PRN ranibizumab treatment for macular edema due to branch retinal vein occlusion[J].,2019,(11):1552-1555.
点击复制

雷珠单抗玻璃体腔按需注射治疗视网膜分支静脉阻塞继发黄斑水肿疗效研究*
分享到：

《陕西医学杂志》[ISSN:1000-7377/CN:61-1281/TN]

卷:
期数:
2019年11期
页码:
1552-1555
栏目:
药物与临床
出版日期:
2019-11-05

文章信息/Info

Title:
Efficacy of intravitreal PRN ranibizumab treatment for macular edema due to branch retinal vein occlusion
文章编号:
DOI:10.3969/j.issn.10007377.2019.11.040
作者:
马为梅; 李春花; 雷晓琴; 周云云; 曾 璐△
西安市第四医院（西安710004）
Author(s):
MA Weimei; LI Chunhua; LEI Xiaoqin; et al
Department of Ophthalmology，Xi’an No4 Hospita（Xi’an 710004）
关键词:
视网膜分支静脉阻塞; 黄斑水肿; 治疗; 雷珠单抗; 玻璃体腔按需注射
Keywords:
Key words Branch retinal vein occlusion; Macular edema; Therapy; Ranibizumab; Pro re nata intravitreal injection
分类号:
R7745
文献标志码:
A
摘要:
摘 要 目的：观察雷珠单抗玻璃体腔（PRN）注射治疗视网膜分支静脉阻塞继发黄斑水肿（BRVOME）的疗效。方法：纳入经临床检查确诊的BRVOME患者80例（80眼）。所有患者均在雷珠单抗玻璃体腔首次注射后行玻璃体腔按需注射（1+PRN）治疗，随访6个月，每个月随访1次，观察最佳矫正视力（BCVA）及光学相干断层扫描（OCT）所测量的黄斑中心凹视网膜厚度（CMT）变化情况及两组注射次数的差异。结果：①治疗前及治疗后6个月患者BCVA分别为（085±050）logMAR及（042±035）logMAR，两者相比差异有统计学意义（P＜005）；缺血型BRVO治疗前及治疗后6个月BCVA分别为（099±047）logMAR及（043±041）logMAR，两者相比差异有统计学意义（P＜005），非缺血型BRVO治疗前及治疗后6个月BCVA分别为（081±053）logMAR及（041±032）logMAR，两者相比差异有统计学意义（P＜005），两组患者间BCVA变化比较差异无统计学意义（P＞005）。②治疗前及治疗后6个月患者CMT分别为（62562±17240）μm和（26027±10181）μm，两者比较差异有统计学意义（P＜001）；缺血型BRVO治疗前及治疗后6个月CMT分别为（63209±14372）μm和（26217±10454）μm；非缺血型BRVO治疗前及治疗后6个月CMT分别为（62142±19010）μm和（25743±12147）μm；与治疗前相比，两组患者治疗后各个时间点CMT均有显著性下降，差异有统计学意义（P＜005）。治疗后各个时间点，两组间CMT比较差异无统计学意义（P＞005）。③6个月内患者的平均注射次数为（26±14）次，非缺血型BRVO平均注射次数为（23±12）次，缺血型BRVO患者的平均注射次数为（32±17）次，两组患者注射次数比较差异无统计学意义（P＞005）。结论：雷珠单抗玻璃体腔按需注射（1+PRN）对缺血型及非缺血型BRVOME患者效果显著，可有效改善视力，减轻黄斑水肿症状，并具有很好的安全性。
Abstract:
Abstract Objective：To evaluate the effect of intravitreal pro re nata （PRN） ranibizumab treatment from the start in macular edema due to branch retinal vein occlusion （BRVOME） Methods：A total of 80 patients（80 eyes） with ME secondary to BRVO were selected as research objects All patients were treated on a pro re nata （PRN） basis after a single intravitreal ranibizumab injection，were retrospectively evaluated The optic examination was conducted at least once a month during 6month followup Best corrected visual acuity （BCVA） and central macular thickness （CMT） were measured Results：①The mean BCVA of the patients was（085±050）logMAR at baseline and （042±035）logMAR at the 6th month （P＜005） The mean BCVA of the ischemic BRVO group was（099±047）logMAR at baseline and （043±041）logMAR at the 6th month （P＜005） Similarly，the mean BCVA of the nonischemic BRVO group was （081±053）logMAR at baseline and （041±032）logMAR at the 6th month （P＜005） Between groups，there was no significant difference in mean BCVA at any examination（P＞005） ②〖LM〗The mean CMT of the patients was（62562±17240）μm at baseline and （26027±10181）μm at the 6th month（P＜001） The mean CMT of the ischemic BRVO group was（63209±14372）μm at baseline and （26217±10454）μm at the 6th month Similarly，the mean CMT of the nonischemic BRVO group was（62142±19010）μm at baseline and （25743±12147）μm at the 6th month Compared with baseline，CMT of the two groups decreased significantly at each time point after treatment （P＜005） At each time point，there was no significant difference in CMT between the two groups （P＞005） ③The average number of injections over 6 months was （26±14） The average number of injections in nonischemic BRVO was （23±12） and that in ischemic BRVO was （32±17） There was no significant difference in the number of injections between the two groups （P＞005） Conclusion：Intravitreal ranibizumab is effective in patients for ME due to ischemic and nonischemic BRVO using PRN from the start It can effectively improve visual acuity，alleviate the symptoms of macular edema，and has good safety

参考文献/References:

[1] Ashraf M，Souka AA，Singh RP Central retinal vein occlusion：Modifying current treatment protocols[J]. Eye（Lond），2016，30（4）：505514 
[2] Rogers S，Mcintosh RL，Cheung N，et al. The prevalence of retinal vein occlusion：pooled data from population studies from the United States，Europe，Asia，and Australia[J]. Ophthalmology，2010，117（2）：313319.
[3] 关晓慧，王 峰 曲安奈德玻璃体腔注射联合格栅样光凝治疗糖尿病黄斑水肿疗效分析［J］陕西医学杂志，2014，43（7）：907908.
[4] 宗巧梅 激光联合玻璃体腔注射小剂量曲安奈德治疗视网膜分支静脉阻塞合并黄斑水肿21例[J]. 陕西医学杂志，2015，44（3）：334335.
[5] 金 昱，石安娜，刘 淼 玻璃体内注射雷珠单抗（Ranibizumab）治疗视网膜静脉阻塞继发黄斑水肿[J]. 眼科新进展，2014，34（9）：855857.
[6] Campochiaro PA，Brown DM，Awh CC，et al. Sustained benefits from ranibizumab for macular edema following branch retinal vein occlusion：12month outcomes of a phase III study[J]. Ophthalmology，2011，118（10）：15941602
[7] Noma H，Funatsu H，Mimura T，et al. Macular sensitivity and morphology after intravitreal injection of triamcinolone acetonide for macular edema with branch retinal vein occlusion[J]. Retina，2012，32：18441852.
[8] 宋艳敏，吕沛霖，屈进学加味桃红四物汤治疗视网膜分支静脉阻塞86例[J].陕西中医，2010，31（9）：11631164.
[9] Pielen A，Mirshahi A，Feltgen N，et al. Ranibizumab for Branch Retinal Vein Occlusion Associated Macular Edema Study （RABAMES）：sixmonth results of a prospective randomized clinical trial[J]. Acta Ophthalmologica，2015，93（1）：e29e37.
[10] 李海辉，王彦荣，顾莉莉 应用频域OCT观察雷珠单抗注射液治疗视网膜静脉阻塞性黄斑水肿的疗效[J]. 陕西医学杂志，2016，45（12）：17301734.
[11] Rouvas A，Petrou P，Ntouraki A，et al. Intravitreal ranibizumab （Lucentis） for branch retinal vein occlusioninduced macular edema：ninemonth results of a prospective study[J]. Retina，2010，30（6）：893902.
[12] Ahn SJ，Ahn J，Woo SJ，et al. Initial dose of three monthly intravitreal injections versus PRN intravitreal injections of bevacizumab for macular edema secondary to branch retinal vein occlusion[J]. Biomed Res Int，2013，13（3），209235

相似文献/References:

[1]水 淼,杨国科,江 江.康柏西普玻璃体腔注射联合普拉洛芬局部给药治疗糖尿病性白内障术后黄斑水肿疗效观察[J].陕西医学杂志,2024,(12):1676.[doi:DOI:10.3969/j.issn.1000-7377.2024.12.018]
　SHUI Miao,YANG Guoke,JIANG Jiang.Efficacy of intravitreal injection of conbercept combined with local administration of pranoprofen on macular edema after diabetic cataract surgery[J].,2024,(11):1676.[doi:DOI:10.3969/j.issn.1000-7377.2024.12.018]

备注/Memo

备注/Memo:
*陕西省科技厅社会发展科技攻关项目（2015SF232） 西安市科技局社会发展引导计划医学研究项目\[SF1513（3）\]
更新日期/Last Update: 2019-11-15